Showing results (31-40 of 396) with videos related to
Sort By:
Pageof 40
European Journal of Cancer (Oxford, England : 1990)|January 8, 2013
Resistance to BRAF-targeted therapy in melanomaRyan J Sullivan, Keith T FlahertyCurrent Oncology Reports|March 2, 2006
Her-2 targeted therapy: beyond breast cancer and trastuzumabKeith T Flaherty, Marcia S BroseClinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2018
Response to Immune Checkpoint Antibodies: Not All Responses Are Created EqualJustine V Cohen, Keith T FlahertyClinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 2, 2015
Pembrolizumab for Treatment of Patients with Advanced or Unresectable MelanomaRyan J Sullivan, Keith T FlahertyClinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2015
New strategies in melanoma: entering the era of combinatorial therapyRyan J Sullivan, Keith T FlahertyClinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2011
New strategies in metastatic melanoma: oncogene-defined taxonomy leads to therapeutic advancesKeith T Flaherty, David E FisherJournal of Skin Cancer|December 17, 2011
BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and ResistanceRyan J Sullivan, Keith T FlahertyJournal of the National Comprehensive Cancer Network : JNCCN|April 30, 2009
Where are we with adjuvant therapy of stage III and IV melanoma in 2009?Leslie A Fecher, Keith T FlahertyPigment Cell & Melanoma Research|January 11, 2014
Cyclin-dependent kinases as therapeutic targets in melanomaDavid M Miller, Keith T FlahertyFuture Oncology (London, England)|August 12, 2009
Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatmentKeiran S M Smalley, Keith T FlahertyPageof 40